Search - tctmd.com

Displaying 81 - 100 of 188

Sort: Relevancy | Date

Oral GLP-1 Drug Danuglipron to Move Forward, but With Tweaks to Dose

News Daily News

Oral GLP-1 Drug Danuglipron to Move Forward, but With Tweaks to Dose

December 01, 2023

Simultaneous Dual Cardioversion of AF Lessens Failure Rates in Obese Patients

News Conference News AHA 2023

Simultaneous Dual Cardioversion of AF Lessens Failure Rates in Obese Patients

November 14, 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

November 11, 2023

FDA Grants Tirzepatide a New Indication for Obesity Management

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

November 08, 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

October 11, 2023

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

News Daily News

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

October 10, 2023

Major GI Events Rare but Real in Weight-Loss Patients on GLP-1 Drugs

News Daily News

Major GI Events Rare but Real in Weight-Loss Patients on GLP-1 Drugs

October 06, 2023

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

GLP-1 Meds Linked to 265 Reports to FDA of Suicidal Ideation: Reuters

News Daily News

GLP-1 Meds Linked to 265 Reports to FDA of Suicidal Ideation: Reuters

September 28, 2023

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle

News Daily News

Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle

September 12, 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

News Conference News ESC 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

August 25, 2023

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

News Daily News

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

August 08, 2023

Vegetarian Diets May Curb Cardiometabolic Risk: Meta-analysis

News Daily News

Vegetarian Diets May Curb Cardiometabolic Risk: Meta-analysis

August 01, 2023

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

News Daily News

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

Michael O'Riordan

July 12, 2023

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

News Daily News

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Michael O'Riordan

July 11, 2023

Oral, Daily Semaglutide Cuts Pounds in Nondiabetic Patients: OASIS 1

News Conference News ADA 2023

Oral, Daily Semaglutide Cuts Pounds in Nondiabetic Patients: OASIS 1

June 29, 2023

Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide

News Conference News ADA 2023

Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide

June 28, 2023

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

May 12, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.